Advertisement

Chemotherapy and Erythropoietin Production

  • C. Pohl
  • A. Moter
  • D. Hasenclever
  • E. M. Woll
  • M. Löffler
  • C. A. Baldamus
Conference paper

Abstract

Erythropoietin (Epo) is a glycoprotein growth factor which controls erythropoiesis in mammals. It is well established that renal Epo production is stimulated solely by anemia and low arterial oxygen tension. While the Epo-deficient anemia of chronic renal insufficiency can now be treated effectively with recombinant human Epo [15], the usefulness of Epo therapy for hyporegenerative nonrenal anemia of malignant or chronic inflammatory disease is still under discussion [1, 5, 10-13, 18]. With regard to these conflicting data more information on Epo levels during chemotherapy is required. In the present study the correlation between the degree of chemotherapy-induced anemia and Epo levels was examined systematically in 24 patients with gastrointestinal neoplasia, high-grade non-Hodgkin’s lymphoma or testicular cancer.

Keywords

Testicular Cancer Bone Marrow Function Proc ASCO Erythropoietin Production Acute Blood Loss 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Birgegard G,Wide L, Simonsson B (1989) Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggest mechanism other than anemia for stimulation. Br J Haematol 72: 462–466PubMedCrossRefGoogle Scholar
  2. 2.
    Brown S, Caro J, Erslev AJ, Murray T (1980) Rise in erythropoietin and hematocrit associated with transient liver enzyme abnormalities in an anephric hemodialysis patient. Am J Med 68: 280PubMedCrossRefGoogle Scholar
  3. 3.
    Eckardt KU, Kurtz A, Hirth P, Scigalla P, Wieczorek L, Bauer C (1988) Evaluation of the stability of human erythropoietin in samples for radioimmunoassay. Klin Wochensch 66: 241–245CrossRefGoogle Scholar
  4. 4.
    Goldberg MA, Gaut CC, Schapira L, Antin JH, Ransil BJ, Antman KH, Eder JP McGarigle CJ, Bunn HF (1991) Erythropoietin gene regulation: from the laboratory to the bedside. In: Gurland HJ, Moran J, Samtleben W, Scigalla P, Wieczorek L (eds) Erythropoietin in renal and non renal anemias. Contrib Nephrol 88: 35 - 45Google Scholar
  5. 5.
    Hellebostad M, Marstrander J, Slordahl SH, Cotes PM, Refsum HE (1990) Serum immunoreactive erythropoietin in children with acute leukemia at various stages of disease - and the effects of treatment. Eur J Haematol 44: 159–164PubMedCrossRefGoogle Scholar
  6. 6.
    Fisher JW, Roh BL (1964) Influence of alkylating agents on kidney erythropoietin production. Cancer Res 24: 983–988PubMedGoogle Scholar
  7. 7.
    Jelkmann W, Wolff M (1991) Bestimmung der Erythropoietin-Aktivitat im Serum. Dtsch Med Wochenschr 6: 230–234Google Scholar
  8. 8.
    Klein, HO (1986) 5-Flourouracil (5-FU), Adriamycin (ADM) and methotrexate (MTX) - a combination protocol ( FAMtx) for treatment of metastasized stomach cancer. Proc ASCO 84: 325Google Scholar
  9. 9.
    Klimo P, Connors J (1985) MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 102: 596–602PubMedGoogle Scholar
  10. 10.
    Ludwig H, Fritz E, Kotzmann H, Höcker P, Gisslinger H, Barnas U (1990) Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322: 1693–1699PubMedCrossRefGoogle Scholar
  11. 11.
    Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL (1990) Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322: 1689–1692PubMedCrossRefGoogle Scholar
  12. 12.
    Oster W, Herrmann F, Cicco A, Gamm H, Zeile G, BruneT, Lindemann A, Schulz G, Mertelsman R (1990) Erythropoietin prevents chemotherapy-induced anemia. Blut 60: 88PubMedCrossRefGoogle Scholar
  13. 13.
    Piroso E, Erslev A, Caro J (1989) Inappropriate increase in erythropoietin titers during chemotherapy. Am J Hemtol 32: 248–254CrossRefGoogle Scholar
  14. 14.
    Rich I (1987) Erythropoietin production by macrophages: cellular response to physiological oxygen tension and detection of erythropoietin gene expression by in situ hybridization. In: Rich I (ed) Molecular and cellular aspects of erythropoietin and erythropoiesis. Springer, Berlin Heidelberg New York, pp 291–310 (NATO ASI series H, vol 8 )Google Scholar
  15. 15.
    Scigalla P, Wieczorek L, Bicker U (1991) Treatment of renal anemia with recombinant human erythropoietin: European experience. In: MB Garnick (ed) Erythropoietin in clinical applications. Dekker, New York, pp 141–182Google Scholar
  16. 16.
    Smith DH, Guarneri CM, Whaling SM,Vokes EE (1988) Erythropoietin response in cancer patients receiving cisplatin. Proc Am Assoc Cancer Res 29: 52Google Scholar
  17. 17.
    William S, Einhorn L (1988) Disseminated germ cell tumors: a comparison of cisplatin plus bleomycin plus either vinblastine (PVB) or VP16 (PEB). Proc ASCO 4:C-390Google Scholar
  18. 18.
    Wood P, Nygaand S, Hrushesky WJM (1988) Cisplatin-induced anemia is correctable with erythropoietin. Blood 72 (Suppl): 52Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • C. Pohl
  • A. Moter
  • D. Hasenclever
  • E. M. Woll
  • M. Löffler
  • C. A. Baldamus

There are no affiliations available

Personalised recommendations